Immutep Announces Abstract Accepted for Presentation at the European Society for Medical Oncology (ESMO) Congress 2026
Rhea-AI Summary
Immutep (NASDAQ: IMMP) announced that an abstract from the investigator-initiated Phase II EFTISARC-NEO trial of its MHC Class II agonist eftilagimod alfa (efti) in soft tissue sarcoma has been accepted as an ePoster for the ESMO Congress 2026, held 23–27 October 2026 in Madrid, Spain.
The abstract focuses on health-related quality of life (HRQoL) during neoadjuvant treatment with efti, pembrolizumab and radiotherapy. It will be available online on the ESMO website from 00:05 CEST on 19 October 2026 (Presentation #3788eP), with the presentation later accessible on Immutep’s website. The first author is Dr. Pawel Teterycz from the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw.
Positive
- None.
Negative
- None.
News Market Reaction – IMMP
On the day this news was published, IMMP declined 2.01%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 14 | Patent announcement | Positive | -3.9% | Fourth U.S. patent expanded protection for eftilagimod alfa combination methods |
| Jul 13 | Clinical update | Negative | +7.5% | Positive survival data accompanied disclosure of TACTI-004 discontinuation |
| Jun 04 | Phase I clinical data | Positive | -4.5% | IMP761 showed safety and statistically significant pharmacodynamic activity |
| May 28 | Clinical data release | Positive | +2.3% | Pooled data linked immune activation with improved overall survival |
| Apr 30 | Quarterly activities report | Negative | -3.2% | TACTI-004 discontinuation and increased loss were disclosed |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions were mixed, with positive clinical or intellectual-property updates sometimes followed by negative price reactions.
Key Terms
hrqol medical
mhc class ii agonist medical
lag-3 medical
soft tissue sarcoma medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23–27 October 2026 in Madrid, Spain.
The abstract reports health-related quality of life (HRQoL) data from EFTISARC-NEO. Details of the accepted abstract and poster are as follows:
| Title | Health-related quality of life (HRQoL) during neoadjuvant treatment with eftilagimod alfa, pembrolizumab and radiotherapy in patients with soft tissue sarcoma (STS) – results from EFTISARC-NEO trial |
| Trial | EFTISARC-NEO (investigator-initiated Phase II; NCT06128863) |
| Session category | ePoster |
| First Author | Pawel Teterycz, M.D., Maria Skłodowska-Curie National Research Institute of Oncology (MSCNRIO), Warsaw, Poland |
| Presentation # | 3788eP |
| Abstract online | Monday, 19 October 2026 at 00:05 CEST (ESMO website) |
The full abstract will be published on the ESMO Congress 2026 website on Monday, 19 October 2026. The presentation will subsequently be made available on Immutep’s website.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding anticipated clinical development, regulatory progress and potential benefits of eftilagimod alfa. These forward-looking statements are based on current expectations, estimates and projections, and involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from those expressed or implied in such statements.
Factors that could cause actual results to differ materially include risks associated with clinical trial outcomes, regulatory developments, and the Company’s ability to advance its product candidates.
Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Immutep undertakes no obligation to update or revise such statements, except as required by applicable law.
Disclaimer
This announcement has been prepared for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, securities in any jurisdiction.
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071; eleanor.pearson@sodali.com
US Investors/Media
Matthew Beck, astr partners
+1 (917) 415-1750; matthew.beck@astrpartners.com
